Schedule of trial outcomes and measures
| Outcome | Measure | Timing (months) | ||
| 0 | 6 | 18 | ||
| Participant recruitment to the trial. | Recruitment against planned recruitment rates. | × | ||
| Participant willingness to be randomised. | Number of people showing an interest and not proceeding or those who withdraw from the control group and give a reason. | × | ||
| Feasibility of collection of clinical measurement data for the proposed clinical trial. | Retrieval of measurements of HbA1c, systolic blood pressure and cholesterol for trial participants from medical record. | × | × | |
| Willingness of participants to be followed up over the 26-week period postrandomisation. | Retention and follow-up rates. | × | ||
| Feasibility of collection of prescribing data on trial participants. | Proportion of medication possession ratio for glucose, blood pressure and lipid-lowering medication obtainable from prescribing data in participant’s medical record. | × | ||
| Feasibility of collecting self-reported questionnaire measures. | Proportion of completed self-reported measures (Demographics and Additional Information Questionnaire; MARS Self-Report Scale; EQ-5D-5L Health Status Questionnaire; Healthcare Utilisation Record Questionnaire (cost measurement); and Health Psychology and Technology Acceptance Questionnaire. | × | × | |
| Feasibility of collecting medical history and baseline medication from medical record. | Proportion of data obtained. | × | ||
| Feasibility and acceptability of the intervention for patients and healthcare professionals (including general practitioners, nurses, receptionists and pharmacists). Qualitative process evaluation. | Data obtained through focus groups, qualitative interviews with patients and healthcare staff. | × | × | |
| Assess reliability of measures of hypothesised mechanism of action and sensitivity to change in response to receipt of SMS messages. Examine relationship between these measures and self-reported adherence, as preliminary process analysis. (Quantitative process evaluation). | Change in quantitative mechanism of action measures and relationship between changes in these measures and self-reported adherence. | × | × | |
| Changes in clinical measurement data. | HbA1c, systolic blood pressure and cholesterol for trial participants from medical record. | × | × | × |
| Information on message delivery and interaction with participants. | Automated reports from messaging service on messages delivered and interactive messaging. | × | × | |
EQ-5D-5L, EuroQol 5-Dimension, 5-Level; HbA1c, glycated haemoglobin; MARS, Medication Adherence Report Scale.